Other Events ·
Jaguar Health, Inc. announced that its subsidiary, Napo Pharmaceuticals, Inc., and Alivus Life Sciences Limited (f/k/a…
JAGXJaguar Health, Inc.
Jaguar Health, Inc. announced that its subsidiary, Napo Pharmaceuticals, Inc., and Alivus Life Sciences Limited (f/k/a Glenmark Life Sciences Limited) entered into a new manufacturing and supply agreement for crofelemer, the active ingredient in Mytesi, which expires on March 31, 2029. The agreement includes minimum purchase commitments from Napo, subject to certain shortfall obligations and capacity constraints. Jaguar Health, Inc. operates in the healthcare industry, developing and commercializing human prescription drug products.